Long-Acting HIV Antiretroviral Therapy (ART): Cabotegravir/Rilpivirine (CAB/RPV)

This guideline provides recommendations for HIV care teams on implementing long-acting injectable HIV treatment, including cabotegravir and rilpivirine.

Author:

NYC Department of Health and Mental Hygiene

Format:

Guideline

Publication Date:

2025

ID:

380432

Audiences

Health Professionals
Nurses
Persons with HIV
Physicians

Focus Area

HIV and AIDS

Topic

Health Care Planning
HIV
Treatment Guidelines Materials

Related Materials

Materials

Tertiary Syphilis-Induced Ocular Syphilis Complicated by Retinal Detachment

Materials

Treatment of Chlamydia and Gonorrhea in Primary Care and Its Patient-Level Variation: An American Family Cohort Study

Materials

Trends in Cervical Precancers Identified Through Population-Based Surveillance — Human Papillomavirus Vaccine Impact Monitoring Project, Five Sites, United States, 2008–2022

Materials

HCV and HIV Coinfection: Decreasing Barriers to an HCV Cure With Use of a Simplified Treatment Algorithm

Back to Results

Long-Acting HIV Antiretroviral Therapy (ART): Cabotegravir/Rilpivirine (CAB/RPV)

Related Materials

CDC NPIN Resources